{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estradiol+infusion", "query": { "intervention": "Estradiol infusion" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 38, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Estradiol+infusion&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T23:01:35.574Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00455962", "title": "Effect of Race on Gonadotropin Responses", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Premenopause", "Healthy" ], "interventions": [ { "name": "Estradiol steroid infusion", "type": "DRUG" }, { "name": "Progesterone steroid infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "FEMALE", "summary": "18 Years to 35 Years · Female only" }, "enrollment_count": 23, "start_date": "2005-01", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2017-07-27", "last_synced_at": "2026-09-04T23:01:35.574Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00455962" }, { "nct_id": "NCT03294694", "title": "Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer", "HER2-Negative Breast Cancer", "Metastatic Epithelial Ovarian Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "PDR001", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2017-11-08", "completion_date": "2020-10-14", "has_results": false, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-09-04T23:01:35.574Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03294694" }, { "nct_id": "NCT02057133", "title": "A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "LY2835219", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "LY3023414", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Loperamide", "type": "DRUG" }, { "name": "Endocrine therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 198, "start_date": "2014-03-10", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-09-04T23:01:35.574Z", "location_count": 13, "location_summary": "Rogers, Arkansas • La Jolla, California • Boston, Massachusetts + 7 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057133" }, { "nct_id": "NCT00003614", "title": "Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "estramustine phosphate sodium", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "18 Years to 120 Years · Male only" }, "enrollment_count": null, "start_date": "1999-02-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-09-04T23:01:35.574Z", "location_count": 27, "location_summary": "Chicago, Illinois • Decatur, Illinois • Peoria, Illinois + 18 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003614" }, { "nct_id": "NCT00004054", "title": "Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "bicalutamide", "type": "DRUG" }, { "name": "estramustine phosphate sodium", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "flutamide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Luteinizing hormone releasing hormone [LHRH] agonist", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 397, "start_date": "2000-01", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-09-04T23:01:35.574Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004054" }, { "nct_id": "NCT03767335", "title": "MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "MEN1611", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Menarini Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2018-11-13", "completion_date": "2024-02-23", "has_results": true, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-09-04T23:01:35.574Z", "location_count": 3, "location_summary": "Fort Lauderdale, Florida • Farmington Hills, Michigan • St Louis, Missouri", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03767335" }, { "nct_id": "NCT02560051", "title": "Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Estramustine", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 19, "start_date": "2015-11", "completion_date": "2017-09-14", "has_results": true, "last_update_posted_date": "2018-11-28", "last_synced_at": "2026-09-04T23:01:35.574Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02560051" }, { "nct_id": "NCT02494713", "title": "Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Degarelix", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Estramustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 4, "start_date": "2015-10", "completion_date": "2017-09-14", "has_results": true, "last_update_posted_date": "2018-11-27", "last_synced_at": "2026-09-04T23:01:35.574Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02494713" }, { "nct_id": "NCT03099174", "title": "This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Breast Neoplasms" ], "interventions": [ { "name": "Xentuzumab", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2017-05-04", "completion_date": "2024-05-16", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-09-04T23:01:35.574Z", "location_count": 6, "location_summary": "Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT03099174" }, { "nct_id": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "SGN-LIV1A", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Chemotherapy (Gemcitabine + Carboplatin or Eribulin)", "type": "DRUG" }, { "name": "Selicrelumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Govitecan", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib (Dose #1)", "type": "DRUG" }, { "name": "Inavolisib (Dose #1)", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "Ribociclib (Dose #2)", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Inavolisib (Dose #2)", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Atirmociclib", "type": "DRUG" }, { "name": "Giredestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1132, "start_date": "2018-03-30", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-04T23:01:35.574Z", "location_count": 20, "location_summary": "Duarte, California • La Jolla, California • Stanford, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Longmont", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03424005" } ] }